The present study was aimed to identify predictive factors of therapy response and survival under the BRAF inhibitor vemurafenib. The data demonstrate that the type of pretreatment strongly influences the outcome of vemurafenib therapy, with a precedent immunotherapy showing a positive, and a prior chemotherapy and kinase inhibitors showing a negative impact on survival, respectively.

READ FULL ARTICLE Curated publisher From Mdlinx